Asset
BELAPECTIN
Galectin Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02407041 | phase2 | completed | 2015-09-01 | 2018-03-01 | Galectin Therapeutics Inc. | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis |
| NCT02421094 | phase2 | completed | 2015-09-01 | 2016-09-27 | Galectin Therapeutics Inc. | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis |
| NCT02462967 | phase2 | completed | 2015-06-01 | 2017-10-01 | Galectin Therapeutics Inc. | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis |
| NCT04332432 | phase1 | completed | 2020-06-16 | 2022-03-09 | Galectin Therapeutics Inc. | GT-032 Belapectin Hepatic Impairment |
| NCT01899859 | phase1 | completed | 2013-07-01 | 2015-02-01 | Galectin Therapeutics Inc. | Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis |
FDA applications (0)
This company has no applications containing this asset.